Hemagglutinin structure and function
Influenza A viruses are divided into 18 different HA subtypes (H1-H18), whereas influenza B viruses have two different lineages (the Yamagata and Victoria lineages). The natural reservoir for influenza viruses is wild aquatic birds, and 16 of these 18 HA subtypes (H1-H16) are resident in the bird population. Genomic RNAs of the other two influenza A subtypes (H17 and H18) have been recently found in bats 2, 3 , although live virus of these two subtypes has yet to be isolated. The influenza virus HA structure (for the H3 subtype from the 1968 influenza pandemic) was first determined in 1981; this was also the first viral antigen from an enveloped virus to be described 4, 5 (Fig. 1 ). The identification, in 1983, of substitutions in HA that account for the differential recognition of avian-type versus human-type receptors (α 2-3-versus α 2-6-linked sialosides) 6 facilitated the structural determination of HA-bound receptor complexes with sialic acid analogs in 1988 7 . Another unknown was whether the precursor HA0 undergoes substantial conformational changes when converting to its fusion-competent form, as HA1 and HA2, and that was answered in 1988: the HA0 structure revealed surprisingly few differences between the cleaved and uncleaved forms 8 , other than at the cleavage site, in contrast with the larger changes suggested recently for some other viral envelope proteins, such as HIV-1 Env 9 . The next burning question was what conformational changes in HA lead to its membrane fusion activity in the low pH of endosomal compartments. The structure of a fragment of the HA stem in 1994 showed the massive rearrangements that HA undergoes to acquire its post-fusion form 10 .
Further questions arose as to whether there are substantial structural differences in the HAs from subtypes in influenza viruses responsible for the other pandemics, such as the 1918 H1N1 Spanish influenza 11, 12 , 1957 H2N2 Asian influenza 13, 14 , and 2009 H1N1 swine-origin pandemic [15] [16] [17] , or in the more recently emerging viruses of concern to human health, such as H5N1 18, 19 , H7N9 [20] [21] [22] , H10N8 [23] [24] [25] , and H6N1 24, 26, 27 , as well as influenza B HA and other influenza A subtypes 3, 19, [28] [29] [30] [31] [32] . This compendium of structures indicated that the HA architecture is highly conserved, but the surface properties and glycosylation patterns differ extensively among influenza subtypes and types. Furthermore, as the virus evolves after entering the human population, the glycans cover more of the HA surface 33, 34 . Influenza A viruses can also be classified phylogenetically into group 1 (H1, H2, H5, H6, H8, H9, H11, H12, H13, H16, H17, and H18) and group 2 (H3, H4, H7, H10, H14, and H15). The main functional differences between these groups arise in the different ways that they interact with their receptor 35 and in the definition of their epitopes 35, 36 , especially in the head region.
HA stem binders
Despite these advances, it was not known until relatively recently whether it was possible to find human antibodies that are able to broadly neutralize influenza virus. The big breakthrough came in 2008-2009 with the isolation and characterization of human bnAbs that could neutralize most influenza A group 1 viruses [37] [38] [39] (Fig. 1) . Surprisingly, those antibodies, such as CR6261 and F10, do not bind to the hypervariable head, as do the strain-specific antibodies that are normally elicited by infection and vaccination; instead, they were found to target the much more highly conserved and less accessible stem region using only the variable heavy chain for interaction 39, 40 . Thus, the HA stem suddenly became of major interest as a bnAb target, and this suggested that a more universal vaccine might be possible. Indeed, back in 1993, a mouse antibody with some heterosubtypic breadth (C179) had been reported to target the HA stem region 41 , but this antibody was largely overlooked by researchers in the influenza field. A crystal structure of C179 some 20 years later confirmed that it bound to the same stem region as these human bnAbs 42 . Further extensive searches then ensued for other human antibodies that could target the HA stem with binding profiles that differed from the first set of bnAbs, which were all derived from the same V H 1-69 germline family and exclusively targeted group 1 HAs. The Crucell group discovered another antibody (CR8020), whose heavy chain is encoded by the V H 1-18 germline gene 43 . CR8020 binds slightly lower down the stem than the original bnAbs and targets group 2 viruses (Fig. 2) . The next major development was the isolation by the Lanzavecchia group of antibody FI6v3, which can target all group 1 and group 2 HAs 44 . FI6v3 arose from a different germline gene family, V H 3-30, and targets the same stem region as the V H 1-69 antibodies, but with a completely different binding mode and in a more conventional way, with interactions from both the light-and heavy-chain variable regions (Fig. 2) . In another major step forward, Crucell then identified an antibody (CR9114) that can bind to both influenza A and influenza B viruses 45 ( Fig. 2) . Such an antibody represents the epitome of what one would want to elicit in a universal vaccine. All of these broadly neutralizing antibodies inhibit the membrane fusion activity of HA by stabilizing the prefusion form of the HA trimer and preventing the conformational changes induced by low pH that release the fusion peptide 39, 41, [43] [44] [45] .
HA head binders
We will return later to stem binders but will first focus on exciting new developments on bnAbs to the head region. It was not clear initially whether bnAbs against the head could be found, as that region is so hypervariable. However, a number of research groups have now identified antibodies to the head that have greater breadth than the isolate-specific antibodies normally elicited by natural infection and vaccination. In 2009, the Takada group reported an antibody (S139/1) that cross-reacts with different influenza virus subtypes (H1, H2, H3, H5, H9, and H13) close to antigenic site B 46 . A flurry of papers in 2011 also reported on head antibodies that have considerable breadth within the H1 subtype (for example, 5J8 47 and CH65 48 ), as well as an exceptional pan-H3 antibody, F045-092, that also had some activity against H1, H2, H5, and H13 subtypes 49 ( Fig. 2 ). These head antibodies interact with the conserved RBS by inserting their H3 or H2 complementarity-determining loops (CDRs) into the same site as the sialic acid receptor, explaining their breadth. Perhaps the archetype antibody against the RBS is C05, which essentially uses a single, long CDR H3 to engage the RBS, thereby minimizing contact with the hypervariable residues that surround the RBS 50 ( Fig. 2) . Indeed, the most effective of these bnAbs to the RBS have smaller binding footprints that emulate, to some extent, the limited surface engaged by the sialic acid receptor 51 . Despite the quite different angles of approach of these antibodies to the HA surface, analysis of CH65 48 , CH67 52 , 5J8 53 , F045-092 51 , 641 I-9 54 , and H2526 54 revealed that a dipeptide corresponding to an aspartic acid hydrophobic motif was the primary antibody motif for recognition of the RBS 54, 55 . Specifically, this dipeptide is located at the tip of the CDR loop that is inserted into the RBS. This observation further underscores that it is feasible to target the RBS for vaccine and therapeutic design.
Design of a more universal vaccine
A number of different families of antibodies have now been found to target the stem region. Originally, most of these antibodies were from the V H 1-69 germline family, including CR6261 and CR9114, with a very hydrophobic CDR H2 that inserts two hydrophobic residues (isoleucine and phenylalanine) at the tip into hydrophobic stem pockets. A conserved tyrosine residue in CDR H3 provides the basis for the interaction with the HA stem. Together, these recognition elements, arising from CDR H2 (IF) and H3 (Y), form the so-called IFY motif 56, 57 . Two other stem-binding bnAbs, FI6v3 44 and 39.29 58 of the V H 3-30 germline family, bind HA at a very different angle and utilize both light and heavy chains for interaction, in contrast to V H 1-69, for which the heavy chain makes the majority, if not all, of the stem interactions. Nonetheless, V H 1-69 and V H 3-30 antibodies have very similar binding footprints and fill the same set of hydrophobic pockets in the HA stem 59 . However, antibodies from the V H 3-30 family use an extended CDR H3 to occupy the same pockets as the IFY motif of the V H 1-69 antibodies. More recently, a number of vaccine-induced antibodies that arise from other heavy-chain germline families have been shown to target this same site 60 . These findings have led to the concept of a headless HA as an immunogen that would focus the immune response on the HA stem and away from the more immunogenic head region 61 .
The main problem was how to design and engineer such a construct, given that the headless HA region comprises three segments: the N-and C-terminal regions of the HA1 chain and the entire HA2 chain. In 2015, two such designs, namely mini-HA and headless HA, were reported by Janssen and ourselves 62 and by the NIH Vaccine Research Institute (VRC) 63 , respectively (Fig. 3a) . These engineered immunogens were tested in mice, monkeys, and ferrets. The immunized animals survived challenge with a lethal dose of virus, thus providing the all-important proof of principle that a protective response could indeed be generated against the HA stem by vaccination. Furthermore, the response was relatively broad: for example, in the immunization studies with the mini-HA #4900 design, a heterologous response was produced in mice against an H1 subtype (A/Puerto Rico/8/1934) that was quite distant from the template (A/Brisbane/59/2007) used for design of the immunogen 62 . Heterosubtypic responses were also elicited against viruses from another subtype (H5, A/Hong Kong/156/1997). Similar results were observed in cynomolgus monkeys: the mini-HA was able to protect against both heterologous and heterosubtypic viruses, in contrast to a trivalent seasonal vaccine that could generate only strain-specific responses 62 . Passive protection against heterosubtypic challenge (H5), resulting from the introduction of serum from the immunized mice into naïve mice, was also observed. The VRC headless HA construct was also displayed on ferritin nanoparticles particles to enhance its immunogenicity 63 (Fig. 3b) . Crystal structures of both mini-HA and headless HA designs indicated some splaying of the headless HA trimers at the base as compared to the full-length HA (Fig. 3c,d) , which is likely attributable to the engineering that involved additional trimerization domains (GCN4 62 or a trimerizing peptide from HIV-1 gp41 63 ) to help stabilize the triple helices in the center of the stem. Notwithstanding this, the neutralizing epitopes were faithfully preserved in these designs, as indicated by their strong binding to known bnAbs such as CR6261 and CR9114.
Besides the mini-HA and VRC headless HA constructs, other stem-based immunogens have been designed and reported [64] [65] [66] [67] [68] [69] . Another proposed approach to elicit heterologous and heterosubtypic immunity to the HA stem was the use of HA chimeras, in which head domains from different subtypes are fused with a single stem domain, to direct the antibody response to the conserved stem region by sequential immunization with different chimeras 70, 71 . Overall, these stem immunogens are currently the most promising for the development of a more universal vaccine, and work is currently in progress to increase the breadth of the response through further design work.
Design of small proteins and peptides against the HA stem domain
Shortly after the first structures of stem bnAbs were determined, Baker and colleagues designed small proteins inspired by the interactions between the antibodies and the HA stem. The concept was to select side chains to fill some of same pockets in the HA stem targeted by antibodies, and then identify protein scaffolds onto which those amino acid side chains could be attached in an appropriate conformation and configuration to optimize binding. Two such designs, HB36 and HB80, bound to H1 and H5 HAs with lownanomolar affinity. The crystal structure of HB36 in complex with 1918/H1 HA showed the remarkable fidelity of the design 72 (Fig. 4) . The designs were then further optimized to produce a 51-residue protein (HB80.4) that was able to bind to all influenza A group 1 HAs and neutralize H1N1 viruses with potencies akin to those of the best bnAbs 73 . The most recent advance in such small-protein designs came from using a massively parallel approach, whereby 22,600 mini-proteins with different backbone scaffolds of 37-43 residues were screened against influenza HA 74 . Binders with very high affinity (K d < 10 nM) and stability (T m > 95 °C) were identified and, importantly, these designed proteins were not found to be immunogenic even after repeated injections in mice. One mini-protein design, HB1.6928.2.3, is smaller than previous designs (Fig. 4) and represents an excellent alternative to bnAbs for prophylaxis and therapy.
In another recent breakthrough, small peptides were designed and characterized against this same site in the HA stem, also based on how bnAbs target the stem, in a collaboration between Janssen and our laboratory 59 . Using the CDR-interacting loops of two bnAbs FI6v3 and CR9114 as templates, cyclic peptides that ) and stem-binding (CR9114 (PDB 4FQI) 45 and FI6v3 (PDB 3ZTJ) 44 ) bnAbs in complex with HA. b, Comparison of the epitopes of four stem-binding bnAbs: CR8020 (PDB 3SDY) 43 , CR6261 (PDB 3GBM) 40 , FI6v3 (PDB 3ZTJ) 44 , and CR9114 (PDB 4FQI) 45 . The epitope of the indicated bnAb is colored lime, and regions corresponding to the epitope of the other three bnAbs are colored white, for comparison. c, Binding and neutralization breadths of CR8020 43 , CR6261 38, 40 , FI6v3 44 , CR9114 45 , F045-092 49, 51 , and C05
50
. The phylogenetic relationship of HAs from influenza B virus and from different influenza A virus subtypes is indicated. A green check mark indicates that either binding, neutralization activity, or in vivo protection has been demonstrated; otherwise, a red cross is shown.
also incorporated non-proteinogenic amino acids were designed to fill the same hydrophobic pockets in the HA stem as the stem-binding bnAbs 59 . The crystal structure of one of these peptides, P7, confirmed that it indeed targets exactly the same highly conserved region in the stem as the bnAbs. These 11-residue peptides bind with low-nanomolar affinity to group 1 HAs and also inhibit the low-pH-induced conformational changes that lead to membrane fusion. This design of a peptide mimic of antibody loops is perhaps the most successful design to date of an antibody surrogate 75 .
Design of a small protein against the HA head
The mode of binding of bnAbs to the HA head has also inspired the design of small proteins that mimic the key interactions of antibody C05 50 with the RBS. The peptide-binding loop from C05 H3 was the basis for the design, for which a scaffold (cystatin) that could incorporate the sequence of this loop in a similar conformation was used as the template 76 (Fig. 5) . The design was further optimized by fusing three of these small protein binders with a natural homotrimer. In this way, the design (HSB.2A) matched the geometry of the HA trimer, and this substantially increased the avidity and reduced the off-rate , Gen4 HA-SS construct (PDB 5C0S) 63 , and mini-HA #4900 construct (PDB 5CJQ) 62 . b, EM reconstruction of a nanoparticle that displays the Gen6 HA-SS construct (EMDB EMD-6332) 63 . c,d, The structural conformations of the stem regions of HA, Gen4 HA-SS (without the trimerizing gp41 peptide region), and mini-HA #4900 (without the trimerizing GCN4 region) are aligned by minimizing their r.m.s. deviation. In c, alignment was performed on a single protomer. In d, alignment was also performed on the trimeric form. Although the protomers from both Gen4 HA-SS and mini-HA #4900 align well with HA, their trimeric forms adopt a more open, splayed conformation at the base as compared to native full-length HA. by more than three orders of magnitude. HSB.2A also had similar breadth and potency to C05 IgG and protected mice against influenza virus in a challenge study. This study now also provides further proof of concept that the information derived from how bnAbs target the RBS can be used to design a small protein that inhibits influenza virus.
Small-molecule antivirals against the HA stem
On the small-molecule front, a small molecule named tert-butylhydroquinone (TBHQ) had been shown to bind influenza HAs (with a K d of 5-50 μ M) and inhibit its fusion activity 77 . The crystal structure of TBHQ bound to H3 and H14 HAs revealed that it interacted with a hydrophobic pocket further up the stem region than the regions targeted by the bnAbs, but could still stabilize protomer interactions in the trimer, accounting for its inhibition of membrane fusion 78 . In 2017, the crystal structure of a broad-spectrum antiviral (umifenovir) that has been sold as an over-the-counter drug in some countries since 1990, in Russia as Arbidol and in China as Enerxin, was determined in complex with HA 79 . This drug is currently manufactured by Pharmstandard in Russia. Our laboratory found that umifenovir indeed interacts with influenza HA and binds in the pocket that was only partially occupied by TBHQ 78 ( Figs. 1 and 6 ). This compound has modest binding affinity (K d ~40-100 μ M) to group 1 and group 2 influenza A viruses, and also acts as a fusion inhibitor. Crystal structures of H3 and H7 HAs with umifenovir showed that a water molecule was also present in the binding pocket 79 . Structure-based design of umifenovir analogs to incorporate a hydroxyl at the position corresponding to the water molecule improved binding to 90-500 nM, depending on the HA 80 . Thus, umifenovir analogs represent promising lead compounds for further improvement of drug binding and stability.
Some resistance mutations have been described that do not seem to interfere directly with either TBHQ or umifenovir binding 81, 82 (Fig. 6 ). Instead, these mutations alter the pH of fusion and slightly raise the susceptible pH for triggering the conformational rearrangements that lead to fusion. Thus, increasing the affinity of umifenovir may make it more difficult for the virus to escape. Such inhibitors now provide yet another target for therapeutic development and further options for combating influenza virus.
Concluding remarks
In the last ten years, immense progress has been made toward developing more effective strategies to combat influenza virus either by vaccination or by therapy. The discovery of human bnAbs to influenza virus proved that it was indeed reasonable and timely to contemplate the design of a more universal vaccine. The determination of a large number of bnAb structures against the HA head and stem has enabled common modes of recognition to be deciphered, even if the antibodies differ in their germline origin and angle of approach to the HA surface 33, 55, 83 . These bnAbs therefore provide blueprints for 78 and umifenovir (right, PDB 5T6S) 79 , has been characterized. HA1 is colored gray and HA2 is colored teal. TBHQ and umifenovir are shown in sphere representation (yellow, carbon; red, oxygen; blue, nitrogen). The receptor-binding site and CR9114 epitope are colored lime and pink, respectively. The Cα of each resistance mutation is shown as a purple sphere. The change in pH of fusion, as measured by hemolysis assay 81, 82 , is indicated for each resistance mutation.
designing candidate immunogens that focus the immune response against the HA stem and the RBS. The headless HA designs and their characterization have convincingly demonstrated the feasibility of this approach.
These bnAbs have also inspired design of small proteins and peptides to specifically target the HA and emulate the neutralization properties and mechanisms of the bnAbs. The finding that small molecules can further target an additional conserved hydrophobic pocket in the HA stem provides yet another opportunity for further design of small molecules as therapeutics against influenza virus. The next few years therefore hold great promise for the design of both new vaccines and new therapies against influenza virus, and it is to be hoped that these will be realized before any new pandemic emerges on the scale of the devastating H1N1 1918 influenza virus.
